Fig. 7

Sensitivity analysis: artemether-lumefantrine (AL) adherence, single low dose primaquine half-life, and ivermectin duration of effectiveness. Change (%) in the simulated mean parasite prevalence compared to the simulated mean parasite prevalence after 1 year of implementation of a baseline strategy, as a result of varying the operational strategy of the intervention. Categories represented in the columns include proportion of the population adhering to the artemether-lumefantrine (AL) regimen, the half-life of single low dose primaquine, and duration of effectiveness at different coverage levels for testing strategies of ivermectin paired with AL. The rows represent results stratified by the pre-intervention mean parasite prevalence in the population as measured by RDT. For all categories, the baseline includes the existing intervention strategy of three rounds of mass test and treat with AL covering 72 % per round of all ages in the population with 60 days between treatment rounds. Baseline AL adherence is 75 %, baseline primaquine half-life is 48 h, and baseline ivermectin duration of effectiveness is 2 days. Centre solid lines represent the simulated median value, blue boxes represent the inter-quartile range, and capped bars represent the upper and lower adjacent values for simulated results using an ensemble of 14 model variants and three random seeds